Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS, Giles F.

Leukemia. 2018 Aug;32(8):1768-1777. doi: 10.1038/s41375-018-0210-1. Epub 2018 Jul 20.

2.

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM.

N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.

PMID:
29860938
3.

A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormone.

Jimenez JJ, DelCanto GM, Popovics P, Perez A, Vila Granda A, Vidaurre I, Cai RZ, Rick FG, Swords RT, Schally AV.

Br J Haematol. 2018 May;181(4):476-485. doi: 10.1111/bjh.15207. Epub 2018 Apr 16.

PMID:
29663325
4.

Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia.

Zheng S, Leclerc GM, Li B, Swords RT, Barredo JC.

Oncotarget. 2017 Dec 31;9(5):5529-5544. doi: 10.18632/oncotarget.23797. eCollection 2018 Jan 19.

5.

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.

Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, Erba HP, Berdeja JG, Tam W, Vardhanabhuti S, Pawlikowska-Dobler I, Faessel HM, Dash AB, Sedarati F, Dezube BJ, Faller DV, Savona MR.

Blood. 2018 Mar 29;131(13):1415-1424. doi: 10.1182/blood-2017-09-805895. Epub 2018 Jan 18.

6.

Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia.

Chapman J, Geyer JT, Khanlari M, Moul A, Casas C, Connor ST, Fan YS, Watts JM, Swords RT, Vega F, Orazi A.

Mod Pathol. 2018 Mar;31(3):429-441. doi: 10.1038/modpathol.2017.148. Epub 2017 Dec 1.

PMID:
29192651
7.

Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.

Swords RT, Azzam D, Al-Ali H, Lohse I, Volmar CH, Watts JM, Perez A, Rodriguez A, Vargas F, Elias R, Vega F, Zelent A, Brothers SP, Abbasi T, Trent J, Rangwala S, Deutsch Y, Conneally E, Drusbosky L, Cogle CR, Wahlestedt C.

Leuk Res. 2018 Jan;64:34-41. doi: 10.1016/j.leukres.2017.11.008. Epub 2017 Nov 11.

8.

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.

Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Pandya R, Bolosky WJ, Poon H, Deininger MW, Collins R, Swords RT, Watts J, Pollyea DA, Medeiros BC, Traer E, Tognon CE, Mori M, Druker BJ, Tyner JW.

Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):E7554-E7563. doi: 10.1073/pnas.1703094114. Epub 2017 Aug 7.

9.

A Case of AML Characterized by a Novel t(4;15)(q31;q22) Translocation That Confers a Growth-Stimulatory Response to Retinoid-Based Therapy.

Watts JM, Perez A, Pereira L, Fan YS, Brown G, Vega F, Petrie K, Swords RT, Zelent A.

Int J Mol Sci. 2017 Jul 11;18(7). pii: E1492. doi: 10.3390/ijms18071492.

10.

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS.

Blood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6.

11.

Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729].

Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE.

Leuk Res. 2017 Aug;59:65. doi: 10.1016/j.leukres.2017.02.007. Epub 2017 May 30. No abstract available.

PMID:
28575698
12.

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.

Swords RT, Watts J, Erba HP, Altman JK, Maris M, Anwer F, Hua Z, Stein H, Faessel H, Sedarati F, Dezube BJ, Giles FJ, Medeiros BC, DeAngelo DJ.

Blood Cancer J. 2017 Feb 3;7(2):e520. doi: 10.1038/bcj.2017.1. No abstract available.

13.

KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.

Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Jonas BA, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE.

Leuk Res. 2016 Nov;50:123-131. doi: 10.1016/j.leukres.2016.09.012. Epub 2016 Sep 28. Erratum in: Leuk Res. 2017 Aug;59:65.

PMID:
27736729
14.

The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2α and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia.

Leclerc GM, Zheng S, Leclerc GJ, DeSalvo J, Swords RT, Barredo JC.

Leuk Res. 2016 Nov;50:1-10. doi: 10.1016/j.leukres.2016.09.007. Epub 2016 Sep 5.

PMID:
27626202
15.

Acute leukemia in adult Hispanic Americans: a large-population study.

Swords R, Sznol J, Elias R, Watts J, Zelent A, Martin E, Vargas F, Bethel-Ellison S, Kobetz E.

Blood Cancer J. 2016 Oct 14;6(10):e484. doi: 10.1038/bcj.2016.94. No abstract available.

16.

Isocitrate dehydrogenase mutations in myeloid malignancies.

Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R.

Leukemia. 2017 Feb;31(2):272-281. doi: 10.1038/leu.2016.275. Epub 2016 Oct 10. Review.

17.

Alpha-defensin-novel synovial fluid biomarker for the diagnosis of periprosthetic joint infection.

Pupaibool J, Fulnecky EJ, Swords RL Jr, Sistrunk WW, Haddow AD.

Int Orthop. 2016 Dec;40(12):2447-2452. Epub 2016 Oct 7. Review.

PMID:
27714447
18.

An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices.

Ma E, Bonthapally V, Chawla A, Lefebvre P, Swords R, Lafeuille MH, Fortier J, Emond B, Duh MS, Dezube BJ.

Clin Lymphoma Myeloma Leuk. 2016 Nov;16(11):625-636.e3. doi: 10.1016/j.clml.2016.08.006. Epub 2016 Aug 10.

19.

Very late relapse of AML after allogeneic hematopoietic cell transplantation is often extramedullary.

Watts JM, Wang XV, Swords RT, Paietta E, Douer D, Lugar SM, Fernandez HF, Rowe JM, Lazarus HM, Tallman MS, Litzow MR.

Bone Marrow Transplant. 2016 Jul;51(7):1013-5. doi: 10.1038/bmt.2016.44. Epub 2016 Mar 14. No abstract available.

20.

Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?

Campuzano-Zuluaga G, Deutsch Y, Salzberg M, Gomez A, Vargas F, Elias R, Kwon D, Goodman M, Ikpatt OF, Chapman JR, Watts J, Vega F, Swords R.

Am J Hematol. 2016 Mar;91(3):277-82. doi: 10.1002/ajh.24271. Epub 2016 Jan 11.

21.

p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study.

Ha CS, Michalek JE, Elledge R, Kelly KR, Ganapathy S, Su H, Jenkins CA, Argiris A, Swords R, Eng TY, Karnad A, Crownover RL, Swanson GP, Goros M, Pollock BH, Yuan ZM.

Mol Oncol. 2016 Jan;10(1):148-56. doi: 10.1016/j.molonc.2015.09.004. Epub 2015 Sep 18.

22.

Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.

Swords RT, Erba HP, DeAngelo DJ, Bixby DL, Altman JK, Maris M, Hua Z, Blakemore SJ, Faessel H, Sedarati F, Dezube BJ, Giles FJ, Medeiros BC.

Br J Haematol. 2015 May;169(4):534-43. doi: 10.1111/bjh.13323. Epub 2015 Mar 2. Erratum in: Br J Haematol. 2015 Oct;171(2):294. Br J Haematol. 2015 Oct;171(2):294.

23.

Targeted therapy of acute myeloid leukemia.

Carneiro BA, Altman JK, Kaplan JB, Ossenkoppele G, Swords R, Platanias LC, Giles FJ.

Expert Rev Anticancer Ther. 2015 Apr;15(4):399-413. doi: 10.1586/14737140.2015.1004316. Epub 2015 Jan 26. Review.

PMID:
25623136
24.

Novel myelofibrosis treatment strategies: potential partners for combination therapies.

Stein BL, Swords R, Hochhaus A, Giles F.

Leukemia. 2014 Nov;28(11):2139-47. doi: 10.1038/leu.2014.176. Epub 2014 Jun 3. Review.

PMID:
24888274
25.

The role of inflammation in leukaemia.

Giles FJ, Krawczyk J, O'Dwyer M, Swords R, Freeman C.

Adv Exp Med Biol. 2014;816:335-60. doi: 10.1007/978-3-0348-0837-8_13. Review.

PMID:
24818729
26.

Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response.

O'Dwyer ME, Swords R, Nagler A, McMullin MF, le Coutre PD, Langabeer SE, Alvarez-Iglesias A, Fan H, Woodman RC, Giles FJ, Conneally E.

Leuk Res. 2014 Mar;38(3):310-5. doi: 10.1016/j.leukres.2013.11.016. Epub 2013 Dec 1.

PMID:
24333114
27.

Perifosine--a new option in treatment of acute myeloid leukemia?

Krawczyk J, Keane N, Swords R, O'Dwyer M, Freeman CL, Giles FJ.

Expert Opin Investig Drugs. 2013 Oct;22(10):1315-27. doi: 10.1517/13543784.2013.826648. Epub 2013 Aug 9. Review.

PMID:
23931614
28.

Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?

Freeman C, Keane N, Swords R, Giles F.

Expert Opin Pharmacother. 2013 Jul;14(10):1417-27. doi: 10.1517/14656566.2013.799138. Epub 2013 May 20.

PMID:
23688047
29.

New prospects for drug development: the hedgehog pathway revealed. Focus on hematologic malignancies.

Pimentel A, Velez M, Barahona LJ, Swords R, Lekakis L.

Future Oncol. 2013 May;9(5):681-97. doi: 10.2217/fon.13.10. Review.

PMID:
23647297
30.

5-Azacytidine for the treatment of myelodysplastic syndromes.

Krawczyk J, Keane N, Freeman CL, Swords R, O'Dwyer M, Giles FJ.

Expert Opin Pharmacother. 2013 Jun;14(9):1255-68. doi: 10.1517/14656566.2013.794222. Epub 2013 Apr 27. Review.

PMID:
23621771
31.

Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia.

Keane N, Freeman C, Swords R, Giles FJ.

Expert Rev Hematol. 2013 Feb;6(1):9-24. doi: 10.1586/ehm.12.68. Review.

PMID:
23373775
32.

In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy?

Swords R, Santini V.

Hematology Am Soc Hematol Educ Program. 2012;2012:74-5. doi: 10.1182/asheducation-2012.1.74. Review.

PMID:
23233563
33.

EPHA3 as a novel therapeutic target in the hematological malignancies.

Keane N, Freeman C, Swords R, Giles FJ.

Expert Rev Hematol. 2012 Jun;5(3):325-40. doi: 10.1586/ehm.12.19. Review.

PMID:
22780212
34.

MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, Zhao B, Bergstrom D, Le Coutre PD, Freedman SJ, Cortes JE.

Leukemia. 2013 Jan;27(1):113-7. doi: 10.1038/leu.2012.186. Epub 2012 Jul 9.

PMID:
22772060
35.

Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.

Swords R, Freeman C, Giles F.

Leukemia. 2012 Oct;26(10):2176-85. doi: 10.1038/leu.2012.114. Epub 2012 Apr 27. Review.

PMID:
22614177
36.

Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia.

Giles F, Mahon FX, Gjertsen B, Swords R, Labar B, Turkina A, Rosti G.

Eur J Clin Invest. 2012 Sep;42(9):1016-26. doi: 10.1111/j.1365-2362.2012.02675.x. Epub 2012 May 1. Review.

PMID:
22548456
37.

The PIM kinases in hematological cancers.

Alvarado Y, Giles FJ, Swords RT.

Expert Rev Hematol. 2012 Feb;5(1):81-96. doi: 10.1586/ehm.11.69. Review.

PMID:
22272708
38.

Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?

Freeman CL, Swords R, Giles FJ.

Expert Rev Hematol. 2012 Feb;5(1):17-26. doi: 10.1586/ehm.11.68. Review.

PMID:
22272701
39.

Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.

Giles F, Rizzieri D, Ravandi F, Swords R, Jacobsen TF, O'Brien S.

Leuk Res. 2012 Apr;36(4):e71-3. doi: 10.1016/j.leukres.2011.12.010. Epub 2012 Jan 9. No abstract available.

40.

Powered bone marrow biopsy procedures produce larger core specimens, with less pain, in less time than with standard manual devices.

Miller LJ, Philbeck TE, Montez DF, Puga TA, Brodie KE, Cohen SC, Spadaccini C, Swords R, Brenner AJ.

Hematol Rep. 2011 Jan 13;3(1):e8. doi: 10.4081/hr.2011.e8. Epub 2011 Jun 18.

41.

The Pim kinases: new targets for drug development.

Swords R, Kelly K, Carew J, Nawrocki S, Mahalingam D, Sarantopoulos J, Bearss D, Giles F.

Curr Drug Targets. 2011 Dec;12(14):2059-66. Review.

PMID:
21777193
42.

Personalized medicine for acute myelogenous leukemia--at the entrance gate.

Swords RT, Dezube BJ, Medeiros BC.

Am J Hematol. 2011 Aug;86(8):631-2. doi: 10.1002/ajh.22060. No abstract available.

43.

A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy.

Swords RT, Anguita J, Higgins RA, Yunes AC, Naski M, Padmanabhan S, Kelly KR, Mahalingam D, Philbeck T, Miller L, Puga TA, Giles FJ, Kinney MC, Brenner AJ.

J Clin Pathol. 2011 Sep;64(9):809-13. doi: 10.1136/jclinpath-2011-200047. Epub 2011 May 23.

PMID:
21606230
44.

Current status of agents active against the T315I chronic myeloid leukemia phenotype.

Burke AC, Swords RT, Kelly K, Giles FJ.

Expert Opin Emerg Drugs. 2011 Mar;16(1):85-103. doi: 10.1517/14728214.2011.531698. Review.

PMID:
21352071
45.

Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer.

Wang M, Medeiros BC, Erba HP, DeAngelo DJ, Giles FJ, Swords RT.

Expert Opin Ther Targets. 2011 Mar;15(3):253-64. doi: 10.1517/14728222.2011.550877. Epub 2011 Jan 10. Review.

PMID:
21219242
46.

Clinical activity of laromustine (Onrigin™) in hematologic malignancies.

Alvarado Y, Swords R, Kelly KR, Giles FJ.

Expert Rev Hematol. 2009 Oct;2(5):481-8. doi: 10.1586/ehm.09.38.

PMID:
21083013
47.

Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias.

Bansal H, Bansal S, Rao M, Foley KP, Sang J, Proia DA, Blackman RK, Ying W, Barsoum J, Baer MR, Kelly K, Swords R, Tomlinson GE, Battiwalla M, Giles FJ, Lee KP, Padmanabhan S.

Blood. 2010 Nov 25;116(22):4591-9. doi: 10.1182/blood-2009-10-247239. Epub 2010 Jul 22.

48.

Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents.

Kelly K, Swords R, Mahalingam D, Giles FJ.

Leuk Lymphoma. 2010 Aug;51(8):1399-413. doi: 10.3109/10428194.2010.491135. Review.

PMID:
20528247
49.

Rotary powered device for bone marrow aspiration and biopsy yields excellent specimens quickly and efficiently.

Swords RT, Kelly KR, Cohen SC, Miller LJ, Philbeck TE, Hacker SO, Spadaccini CJ, Giles FJ, Brenner AJ.

J Clin Pathol. 2010 Jun;63(6):562-5. doi: 10.1136/jcp.2009.072843. Epub 2010 Apr 19.

PMID:
20404008
50.

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.

Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K, Padmanabhan S, O'Dwyer M, Nawrocki ST, Giles FJ, Carew JS.

Blood. 2010 May 6;115(18):3796-800. doi: 10.1182/blood-2009-11-254862. Epub 2010 Mar 4.

Supplemental Content

Loading ...
Support Center